1SorianoA,Chamolin R, Mccormick G, et al. Maintenance therapy with 5 - agacitidine after allogenneic stem all transplantation for acutem ydogenous leukemia and high - risk myelodysplastic syndrome a dese and schedule finding study. Blood, 2005, 108 (1): 104.
2Soriano A, Braitah F, Garcia G, et al. Combination of 5- agacitidine and valproic acid in advanced solid cancers: a phase I study[J]. Proc Asco,2007, 25(8) : 3547.
3Soriano AO, YangH, Faderl S, et al. Safety and caincal activity of the combination of 5 -agacitidine, valproic acid and alltrans retinoic acid in acutemydaid[J]. Blood, 2007, 110(7) : 2302 - 2308.
2DAVID P S,RICHARD M S.Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes[J].Hematol Oncol Clin N Am,2010,24:389-406.
3KANTARJIAN H,ISSA J P,ROSENFELD C S,et al.Decitabine improves patient outcomes in myelodysplastic syndromes:results of a phase Ⅲ randomized study[J].Cancer,2006,106:1794-1803.
4WIJERMANS P,LUBBERT M,VERHOEF G,et al.Low-dose 5-aza-2′-deoxycytidine,a DNA hypomethylating agent,for the treatment of high-risk myelodysplastic syndrome:a multicenter phase Ⅱ study in elderly patients[J].J Clin Oncol,2000,18:956-962.
5GAUTAM B,SAMIH E A,FARHAD R,et al.Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine[J].Leukemia & Lymphoma,2008,49:690-695.
6Oki Y, Aoki E, Issa lP.Decitabine-bedside to bench [ J].Crit Rev Onclo Hematol, 2007,61 ( 2 ) : 140-152.
7Gryn J,Zeigler ZR,Shadduck RK,et al.Treatment of mye- lodysplatic syndromes with 5-azacytidine[J].Leuk Res,2002,26(10) : 893-897.
8Steensma DP, Baer MR, Slack JL, et al.Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes:the alternative dosing for outpatient treatment (ADOPT) trial [ J ].J Clin Oncol, 2009,27(23 ) : 3842-3848.
9Borthakur G,Ahdab SE,Ravndi F,et al.Activity of decita- bine in patients with myelodysplastic syndrome previously treated with azacitidine [ J ].Leuk Lymphoma, 2008,49 ( 4 ) : 690-695.
10Kantarjian H,Oki Y,Gareai-Manero G,et al.Results of a randomized study of 3 schedules of low-dosedecitabine in higher-risk myelodysplastic syndrome and chronic mye- lomonoeytie leukemia[J ].Blood, 2007,109( 1 ) : 52-57.
